Cancer Research Cell Death Mechanisms and Cancer Therapy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tseng, J.-C.
Right arrow Articles by Meruelo, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tseng, J.-C.
Right arrow Articles by Meruelo, D.
[Cancer Research 64, 6684-6692, September 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Using Sindbis Viral Vectors for Specific Detection and Suppression of Advanced Ovarian Cancer in Animal Models

Jen-Chieh Tseng, Alicia Hurtado, Herman Yee, Brandi Levin, Christopher Boivin, Marta Benet, Stephanie V. Blank, Angel Pellicer and Daniel Meruelo

New York University Cancer Institute, the Rita J. and Stanley H. Kaplan Comprehensive Cancer Center, and the New York University Gene Therapy Center, New York University School of Medicine, New York, New York

We studied the therapeutic value of Sindbis vectors for advanced metastatic ovarian cancer by using two highly reproducible and clinically accurate mouse models: a SCID xenograft model, established by i.p. inoculation of human ES-2 ovarian cancer cells, and a syngenic C57BL/6 model, established by i.p. inoculation of mouse MOSEC ovarian cancer cells. We demonstrate through imaging, histologic, and molecular data that Sindbis vectors systemically and specifically infect/detect and kill metastasized tumors in the peritoneal cavity, leading to significant suppression of the carcinomatosis in both animal models. Use of two different bioluminescent genetic markers for the IVIS Imaging System permitted demonstration, for the first time, of an excellent correlation between vector delivery and metastatic locations in vivo. Sindbis vector infection and growth suppression of murine MOSEC tumor cells indicate that Sindbis tumor specificity is not attributable to a species difference between human tumor and mouse normal cells. Sindbis virus is known to infect mammalian cells using the Mr 67,000 laminin receptor. Immunohistochemical staining of tumor cells indicates that laminin receptor is elevated in tumor versus normal cells. Down-regulated expression of laminin receptor with small interfering RNA significantly reduces the infectivity of Sindbis vectors. Tumor overexpression of the laminin receptor may explain the specificity and efficacy that Sindbis vectors demonstrate for tumor cells in vivo. We show that incorporation of antitumor cytokine genes such as interleukin-12 and interleukin-15 genes enhances the efficacy of the vector. These results suggest that Sindbis viral vectors may be promising agents for both specific detection and growth suppression of metastatic ovarian cancer.




This article has been cited by other articles:


Home page
Cancer Res.Home page
C.-L. Chang, Y.-C. Tsai, L. He, T.-C. Wu, and C.-F. Hung
Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70
Cancer Res., October 15, 2007; 67(20): 10047 - 10057.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J.V. Vaha-Koskela, J. P. Kallio, L. C. Jansson, J. E. Heikkila, V. A. Zakhartchenko, M. A. Kallajoki, V.-M. Kahari, and A. E. Hinkkanen
Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Cancer Res., July 15, 2006; 66(14): 7185 - 7194.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J.-C. Tseng, P. B. Zanzonico, B. Levin, R. Finn, S. M. Larson, and D. Meruelo
Tumor-Specific In Vivo Transfection with HSV-1 Thymidine Kinase Gene Using a Sindbis Viral Vector as a Basis for Prodrug Ganciclovir Activation and PET
J. Nucl. Med., July 1, 2006; 47(7): 1136 - 1143.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
A. Diatta, E. Piver, C. Collin, P. Vaudin, and J.-C. Pages
Semliki Forest virus-derived virus-like particles: characterization of their production and transduction pathways
J. Gen. Virol., November 1, 2005; 86(11): 3129 - 3136.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.